Pacira Pharmaceuticals, Inc.

10578 Science Center Drive
Suite 125
San Diego, CA 92121
(858) 625 2424

5 Sylvan Way
Parsippany, NJ 07054
(973) 254 3560

TAKING CARE OF PATIENTS, TODAY AND TOMORROW

SEC Filings

10-K
PACIRA PHARMACEUTICALS, INC. filed this Form 10-K on 03/01/2017
Entire Document
 << Previous Page | Next Page >>

Other Income (Expense)
The following table provides information regarding other income (expense) during the periods indicated, including percent changes (dollar amounts in thousands):
 
Year Ended December 31,
 
2016 versus
2015
 
2015 versus
2014
 
2016
 
2015
 
2014
 
% Increase / (Decrease)
Interest income
$
1,323

 
$
678

 
$
382

 
95
 %
 
77
 %
Interest expense
(7,061
)
 
(7,725
)
 
(8,278
)
 
(9
)%
 
(7
)%
Loss on early extinguishment of debt

 
(52
)
 

 
(100
)%
 
N/A

Royalty interest obligation

 
(71
)
 
(323
)
 
(100
)%
 
(78
)%
Other, net
(82
)
 
(165
)
 
(159
)
 
(50
)%
 
4
 %
Total other expense, net
$
(5,820
)
 
$
(7,335
)
 
$
(8,378
)
 
(21
)%
 
(12
)%
% of total revenue
(2
)%
 
(3
)%
 
(4
)%
 
 
 
 

Total other expense, net decreased by 21% in 2016 versus 2015 largely due to a decrease in interest expense arising from a $0.6 million increase in capitalized interest, primarily on construction of our new manufacturing suites and an increase in interest income as a result of higher average investment returns. We had no expenses for our DepoCyt(e) royalty obligation and loss on early extinguishment of debt in 2016.
Total other expense, net decreased by 12% in 2015 versus 2014 primarily due to decreases in both interest expense and our royalty interest obligation and an increase in interest income. The decrease in interest expense was primarily due to a $0.5 million increase in capitalized interest on the construction of our new manufacturing suites. The increase in interest income was due to higher investment balances and longer duration investments, and the decrease in our royalty interest obligation was due to our royalty interest assignment agreement with Paul Capital Advisors, LLC that ended on December 31, 2014.
Income Tax Expense
The following table provides information regarding our income tax expense during the periods indicated, including percent changes (in thousands):
 
Year Ended December 31,
 
2016 versus
2015
 
2015 versus
2014
 
2016
 
2015
 
2014
 
% Increase / (Decrease)
Income tax expense
$
105

 
$
264

 
$
173

 
(60
)%
 
53
%
Effective tax rate
0
 %
 
12
%
 
(1
)%
 
 
 
 
We recorded tax provisions of $0.1 million, $0.3 million and $0.2 million for the years ended December 31, 2016, 2015 and 2014, respectively. Since our deferred tax assets are fully offset by a valuation allowance, our total income tax expense includes only current tax expense. The 2016 and 2014 tax provisions consist principally of minimum state taxes. The 2015 tax provision reflects federal alternative minimum tax as well as state taxes.
Liquidity and Capital Resources
Since our inception in 2006, we have devoted most of our cash resources to manufacturing, research and development and selling, general and administrative activities related to the development and commercialization of EXPAREL. We are highly dependent on the commercial success of EXPAREL, which we launched in April 2012. We have financed our operations primarily with the proceeds from the sale of convertible senior notes, convertible preferred stock, common stock, secured and unsecured notes, borrowings under debt facilities, product sales and collaborative licensing and milestone revenue. As of December 31, 2016, we had an accumulated deficit of $346.2 million, cash and cash equivalents and short-term investments of $172.6 million and working capital of $198.3 million.
Summary of Cash Flows
The following table summarizes our cash flows from operating, investing and financing activities for the years ended December 31, 2016, 2015 and 2014 (in thousands):

55

 << Previous Page | Next Page >>

Contact Investor Relations:
Susan Mesco
(973) 451-4030
Susan.Mesco@pacira.com


IHI/NPSF Project Seeks to Improve the Assessment and Management of Acute Pain
Click here for more...